Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca CEO Soriot tops FTSE 100 pay-out charts in 2020 - report

08/19/2021 | 04:32am EDT
FILE PHOTO: Chief Executive of AstraZeneca Pascal Soriot leaves after appearing at a commons science committee hearing at Portcullis House in London

LONDON (Reuters) - Pascal Soriot, the chief executive of COVID-19 vaccine maker AstraZeneca, was Britain's highest paid company boss in 2020, a year when the average FTSE 100 leader saw their pay fall by almost a fifth, a report on Thursday showed.

Soriot, whose handling of the pandemic response has drawn criticism despite the company producing its vaccine at cost price, took home 15.45 million pounds ($21.25 million), a report from the High Pay Centre said.

That compares with median pay for CEOs in Britain's flagship stock index of 2.69 million pounds, down from 3.25 million pounds in 2019, the report found, but still 86 times the median earnings for the average UK worker.

Shareholders had demanded bosses share the financial pain as companies across a range of sectors experienced a tough year, with lockdowns in many countries hitting sales.

The proportion of companies paying bonuses dropped to 64% from 89% in 2019, while 77% paid out long-term incentives based on performance over the previous 3-5 years, compared to 82% the previous year.

Of the nine companies which took public money through the British government's furlough scheme, the average CEO pay was 2.2 million pounds.

"CEO pay packages are designed to reflect the experience of shareholders, employees and other stakeholders so in one sense the lower pay levels this year show the system working as intended," said High Pay Centre Director Luke Hildyard.

"On the other hand, these are still very generous rewards...at a time when, in general, government support for the economy has probably been more important to the survival and success of the UK's biggest companies than the decisions of their executives."

Rounding out the top five earners were Experian's Brian Cassin, with 10.3 million pounds; CRH's Albert Manifold, with 9.92 million pounds; Reckitt Benckiser's Laxman Narasimhan, with 9.24 million pounds, and Berkeley's Rob Perrins, with 8.03 million pounds, the report said.

($1 = 0.7271 pounds)

(Reporting by Simon Jessop; Editing by Kirsten Donovan)

By Simon Jessop

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.22% 8795 Delayed Quote.20.08%
EXPERIAN PLC -0.53% 3203 Delayed Quote.15.34%
RECKITT BENCKISER GROUP PLC -0.73% 5448 Delayed Quote.-16.72%
THE BERKELEY GROUP HOLDINGS PLC -0.23% 4290 Delayed Quote.-9.53%
All news about ASTRAZENECA PLC
10/15ASTRAZENECA : U.S. will accept mixed doses of vaccines from international travelers
10/15ASTRAZENECA : Imfinzi plus tremelimumab significantly improved overall survival in HIMALAY..
10/15GT CAPITAL : Donates 3,000 COVID-19 Vaccine Doses to Government of Makati, Philippines
10/15ASTRAZENECA : JP Morgan remains its Buy rating
10/15AstraZeneca Says Study in Liver Cancer Meets Objective
10/15ASTRAZENECA : UBS remains its Buy rating
10/15ASTRAZENECA : Says Phase 3 Trial of Potential Imfinzi-Tremelimumab Combination Therapy Mee..
10/15ASTRAZENECA : Japan to Donate Almost 2 Million AstraZeneca COVID-19 Shots to Philippines
10/15CSL : Reaffirms Commitment to Manufacture 50 Million Doses of AstraZeneca Vaccine
10/15ASTRAZENECA : Liver Cancer Combo Therapy Improves Patient Survival in Late-Stage Study
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 590 M - -
Net income 2021 4 919 M - -
Net Debt 2021 24 667 M - -
P/E ratio 2021 34,5x
Yield 2021 2,33%
Capitalization 187 B 187 B -
EV / Sales 2021 5,96x
EV / Sales 2022 4,84x
Nbr of Employees 76 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Last Close Price 120,92 $
Average target price 138,73 $
Spread / Average Target 14,7%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC20.08%187 492
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.13.20%232 621